 The combinative therapy of Endostar, Vinorelbine and cisplatin has been shown to increase response rate and survival in patients pts with advanced NSCLC and is sFDA-approved for this indication. However, there are limited data on the safety and efficacy of Endostar in combination with other widely used chemotherapy doublets for NSCLC. Clinical data proved that Endostar was a wild spectrum and safe antiangiogenesis factor which could suppress almost 65 kinds of tumor mass in animal models and affect about 12 percent human genome. In this clinical trial, there will be 160 patients enrollment, giving Docetaxel 75mgm2,iv, d1, every 3 weeks plus Endostar7.5mgm2day, iv, d1-d14, every 3 weeks or Docetaxel with placebo. Well evaluate the efficacy and safety of the Docetaxel plus Endostar treatment to NSCLC and hope to provide a promising regimen to advanced lung cancer patients. 